IART Earnings

IART reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 434.35M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.79 by 0%. The stock experienced a -2.24% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following IART's earnings announcement on 2026-02-26, the stock price moved by -2.24% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, IART's stock price tends to shift by an average of 7.38% in the 10 days leading up to earnings and -1.14% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate IART's annual revenue to reach 392.15M, while the EPS is projected at 0.49. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between IART's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, IART's stock price typically moves by 7.38% in the 10 days before its earnings and -1.14% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.49 and revenue of 392.15M.

The earnings call presents a mixed outlook. While there are positive elements like cost-saving initiatives, product relaunches, and a strong demand forecast, there are also negatives such as revised downward guidance, declining margins, and cash flow issues. The Q&A reveals management's cautious approach and some uncertainty, particularly regarding MediHoney remediation and market impacts of CMS changes. Despite some growth and strategic product shifts, the overall sentiment is balanced by these uncertainties, leading to a neutral stock price prediction over the next two weeks for this mid-cap company.